保留比值受损肺功能的轨迹与死亡率:鹿特丹研究
在鹿特丹人群队列中,7.1%的受试者存在保留比值受损肺功能(PRISm);复检者中15.7%转为正常、49.4%转为慢阻肺。PRISm与全因死亡(HR 1.6,95%CI 1.2-2.0)和心血管死亡(HR 2.8,95%CI 1.5-5.1)风险升高相关,且1年内死亡者70.0%合并心血管疾病。
要点
- PRISm人群异质,复检时近半数进展为慢阻肺。
- PRISm与全因及心血管死亡风险升高独立相关。
- PRISm短期死亡者多合并心衰或冠心病。
核心结论
- PRISm与死亡率增加相关,包含至少三个亚组:进展为慢阻肺者、高心血管负担且早期死亡者、持续PRISm且肺功能正常年龄相关下降者。
研究设计与样本
- 基于鹿特丹研究(人群为基础的前瞻性队列),纳入5487名受试者(年龄69.1±8.9岁;7.1%为PRISm),其中1603人在4.5年后复检。
主要发现
- 复检的PRISm受试者中15.7%转为正常肺功能,49.4%转为慢阻肺。
- 新发PRISm者FEV1年下降中位数-92.8 mL·年-1(IQR -131.9至-65.8),FVC -93.3 mL·年-1(IQR -159.8至-49.1)。
- 持续PRISm者FEV1年下降-30.2 mL·年-1(IQR -67.9至-7.5),与持续正常对照(-39.6 mL·年-1,IQR -64.3至-12.7)相似。
- 5459名同意随访者中692人(12.7%)死亡(最长随访9.3年):正常对照10.3%、PRISm 18.7%、慢阻肺20.8%。
- PRISm与全因死亡(HR 1.6,95%CI 1.2-2.0)和心血管死亡(HR 2.8,95%CI 1.5-5.1)风险升高相关;慢阻肺GOLD 2-4亦升高(全因HR 1.7,95%CI 1.4-2.1;心血管HR 2.1,95%CI 1.2-3.6)。
关键数值与推荐
- PRISm定义:FEV1/FVC≥0.7且FEV1<80%。
- 慢阻肺定义:FEV1/FVC<0.7。
- 正常对照定义:FEV1/FVC≥0.7且FEV1≥80%。
临床怎么用
- 对PRISm人群应评估心血管合并症,尤其心衰或冠心病。
- PRISm患者需随访肺功能,警惕进展为慢阻肺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preserved ratio impaired spirometry (PRISm) is a heterogeneous condition but its course and disease progression remain to be elucidated. We aimed to examine its prevalence, trajectories and prognosis in the general population.In the Rotterdam Study (population-based prospective cohort) we examined prevalence, trajectories and prognosis of subjects with normal spirometry (controls; forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ≥0.7, FEV1 ≥80%), PRISm (FEV1/FVC ≥0.7, FEV1 <80%) and chronic obstructive pulmonary disease (COPD) (FEV1/FVC <0.7) at two study visits. Hazard ratios with 95% confidence intervals for mortality (until December 30, 2018) were adjusted for age, sex, body mass index, current smoking and pack-years.Of 5487 subjects (age 69.1±8.9 years; 7.1% PRISm), 1603 were re-examined after 4.5 years. Of the re-examined PRISm subjects, 15.7% transitioned to normal spirometry and 49.4% to COPD. Median lung function decline was highest in subjects with incident PRISm (FEV1 -92.8 mL·year-1, interquartile range (IQR) -131.9- -65.8 mL·year-1; FVC -93.3 mL·year-1, IQR -159.8- -49.1 mL·year-1), but similar in persistent PRISm (FEV1 -30.2 mL·year-1, IQR -67.9- -7.5 mL·year-1; FVC -20.1 mL·year-1, IQR -47.7-21.7 mL·year-1) and persistent controls (FEV1 -39.6 mL·year-1, IQR -64.3--12.7 mL·year-1; FVC -20.0 mL·year-1, IQR -55.4-18.8 mL·year-1). Of 5459 subjects with informed consent for follow-up, 692 (12.7%) died during 9.3 years (maximum) follow-up: 10.3% of controls, 18.7% of PRISm subjects and 20.8% of COPD subjects. Relative to controls, subjects with PRISm and COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2-4 had increased all-cause mortality (PRISm: HR 1.6, 95% CI 1.2-2.0; COPD GOLD 2-4: HR 1.7, 95% CI 1.4-2.1) and cardiovascular mortality (PRISm: HR 2.8, 95% CI 1.5-5.1; COPD 2-4: HR 2.1, 95% CI 1.2-3.6). Mortality within <1 year was highest in PRISm, with patients often having cardiovascular comorbidities (heart failure or coronary heart disease; 70.0%).PRISm is associated with increased mortality and this population encompasses at least three distinct subsets: one that develops COPD during follow-up, a second with high cardiovascular burden and early mortality, and a third with persistent PRISm and normal age-related lung function decline.
引用
- Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J. 2020. PMID: 31601717. doi:10.1183/13993003.01217-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。